(Q46363886)

21 December 2017

review article

1 reference

title

Alzheimer disease and other dementias (English)

1 reference

21 December 2017

0 references

2

1 reference

21 December 2017

author name string

Gustavo Alva

series ordinal

1

1 reference

21 December 2017

publication date

1 November 2003

1 reference

21 December 2017

Clinics in geriatric medicine

published in

1 reference

21 December 2017

volume

19

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

763-776

1 reference

21 December 2017

Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in the oldest old

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Estimated prevalence of Alzheimer's disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Prevalence of dementia in the 'oldest old' of a Dutch community

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Age-specific incidence of Alzheimer's disease in a community population.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The spectrum of behavioral changes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Influence of age on clinical and psychometric assessment of subjects with very mild or mild dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The Mini-Mental State Examination: A Comprehensive Review

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Correlation between rates of brain atrophy and cognitive decline in AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Psychotropics and drug interactions in the elderly patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The Natural History of Alzheimer's Disease: A Brain Bank Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The incremental direct costs associated with behavioral symptoms in AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cognitive and behavioral effects of quetiapine in Alzheimer disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Valproic acid treatment of agitation in dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cholinergic markers in elderly patients with early signs of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Topographical distribution of neurochemical changes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Monoamine neurons in aging and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cognitive functions of cortical acetylcholine: toward a unifying hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cholinergic dysfunction in diseases with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Problem behaviour, caregiver reactions, and impact among caregivers of persons with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Excitatory amino acids and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Ultrastructural studies of the cells forming amyloid fibers in classical plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Amyloidosis of the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Alzheimer neuropathologic alterations in aged cognitively normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Absence of cognitive impairment or decline in preclinical Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Prevalence and outcomes of vascular cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Practice parameter for diagnosis and evaluation of dementia. (summary statement) Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Absence of vascular dementia in an autopsy series from a dementia clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Vascular dementia: a diagnosis running out of time

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Tau is a candidate gene for chromosome 17 frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

Corticobasal degeneration. A clinical study of 36 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2803%2900028-4

7 January 2021

10.1016/S0749-0690(03)00028-4

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017